Derek DiRocco - 19 Feb 2026 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Director
Signature
/s/ Adam Levy, Attorney-in-fact
Issuer symbol
MLYS
Transactions as of
19 Feb 2026
Net transactions value
$0
Form type
4
Filing time
20 Feb 2026, 19:47:02 UTC
Previous filing
05 Nov 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
DiRocco Derek Director 150 N. RADNOR CHESTER RD., SUITE F200, RADNOR /s/ Adam Levy, Attorney-in-fact 20 Feb 2026 0001792061

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLYS Common Stock Award $0 +6,200 $0.000000 6,200 19 Feb 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Award $0 +8,300 $0.000000 8,300 19 Feb 2026 Common Stock 8,300 $28.06 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Stock Units ("RSUs") are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant.
F2 Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the RSUs and options for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon settlement of the RSUs, or exercise of the options, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the RSUs or option and underlying common stock, as applicable.
F3 The stock option vests in 12 substantially equal monthly installments following the date of grant.